Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

Aziza T. Shad, Jeffrey S. Huo, Courtney Darcy, Amal Abu-Ghosh, Giuseppe Esposito, Mary Jo Holuba, Nancy Robey, Kenneth R. Cooke, Heather J. Symons, Allen R. Chen, Nicolas J. Llosa

Research output: Contribution to journalArticlepeer-review

Abstract

To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.

Original languageEnglish (US)
Article numbere26257
JournalPediatric Blood and Cancer
Volume64
Issue number3
DOIs
StatePublished - Mar 1 2017

Keywords

  • Hodgkin lymphoma
  • anti-PD1
  • haploidentical bone marrow transplant
  • immunotherapy
  • nivolumab
  • relapse

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report'. Together they form a unique fingerprint.

Cite this